|
|
|
|
|
Novo Nordisk 
|
|
Novo Nordisk was founded during 1923 having its headquarters situated at Bagsvaerd in Denmark for manufacturing and marketing the pharmaceutical products and related services. Ever since its establishment, the company is enjoying the foremost position in diabetes care with the widest range of anti-diabetic product category in the industry. This includes the most latest and excellent products within the insulin delivery system sector. Besides this, Novo Nordisk is ranked the zenith position in several other sectors like Haemostasis management, growth hormone therapy as well as hormone replacement therapy – HRT.
Besides, company’s apex status across the world in the diabetes care and strong belief of being the strongest follower of ‘triple bottom line’ Novo Nordisk has supported the International Diabetes Federation’s Unite for Diabetes campaign which has succeeded in obtaining the United Nation’s Resolution on Diabetes. Novo Nordisk is the healthcare company and is adored as the major company in diabetes care.
The company is committed to produce and sell the pharmaceutical products and services that are poised to make the vital difference to the patients, the medical profession and the society on the whole. The company employs nearly 23,600 people in around 79 nations and sells its products in almost 179 countries across the world today.
The major and reputed product range of Novo Nordisk includes several sectors like:
Diabetic Care: Levemir – the Basal Insulin Analogue, Novo-Rapid for Rapid-acting Insulin Analogue and Novo Mix 30 for Dual-Release Insulin Analogue
Haemostasis Management: Novo Seven – Recombinant Factor VIIa Growth Hormones: NordiFlex and Norditropin – the First pre-filled multi-dose hGH Pen
|
|
|
|
|
|
|
Senkyo Co
, Amgemn
, Wetson Pharmaceuticals
, AstraZeneka
, Eishai Co
, Glaksosmithkline
, Bohringer Ingelheim
, Sanophi Aventis
, Ganentech
, H Lundback
|
|
|
|
|
| Latest News About novo nordisk |
|
|
|
Through Val Brickates Kennedy, MarketWatch. BOSTON (MarketWatch) -- drug sectors general reference points afternoon became Tuesday, with USAaufgeführten shares of Danish gemischt...More |
|
|
|
|
Novo Nordisk, the worldand the largest manufacturer of diabetes treatments, ... Under the decision, Novo Nordisk and Genentech, against license certain Patente. becomes...More |
|
|
|
|
Oct. 24--CLAYTON, NC -- construction of Novo Nordiskand $12 million arrangements expansion wasnandt has, but that didnandt stop contractor of celebrations concludes it,....More |
|
|
|
Danish shares close under, led through AP Moeller,... - Color
Color - On the 27th Okt, 2006
COPENHAGEN (AFX) - Novo Nordisk WHEN its control retained for the entire year 2006 after setting up of an operating profit of 7,011 bln dkr for the first nine months....More |
|
|
|
|
LONDON: Shares in Novo Nordisk, fell the worldand that insulin manufacturer leads, 21 percent on Wednesday morning after it cut its salary prediction. ....More |
|
|
|
|
In its year report for 1998, Novo Nordisk announced first its intention to demerge. andquot; it is our goal that public health, enzyme business and our USA discovery....More |
|
|
|
|
Albert L. Jacobs, Jr., Rosenman and Colin, New York city, has, intervene argues for Novo Nordisk, A/S, et al. On the composition, mark was H. sparrow. ....More |
|
|
|
|
COPENHAGEN (AFX) - share prices were under in midmorning trade, led through down Novo Nordisk, that follows classifies a broker more low, dealers said. ....More |
|
|
|
|
Belo horizons - measure should be published today. The tax guilt release of Investitionsgüterern, the change of treatment for financial uses taxes and that....More |
|
|
|
|
COPENHAGEN (AFX) - Novo Nordisk, AS said has that it 2.14 mln of its own B-shares of Novo AS, its possession firm, value attained a sum of 646 mln dkr. ....More |
|
|
|
|
|
|
|
